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Advanced head and neck cancers are difficult to manage despite the large treatment arsenal currently available. The multidisci-
plinary effort to increase disease-free survival and diminish normal tissue toxicity was rewarded with better locoregional control
and sometimes fewer side effects. Nevertheless, locoregional recurrence is still one of the main reasons for treatment failure. Today,
the standard of care in head and neck cancer management is represented by altered fractionation radiotherapy combined with
platinum-based chemotherapy. Targeted therapies as well as chronotherapy were trialled with more or less success. The aim of the
current work is to review the available techniques, which could contribute towards a higher therapeutic ratio in the treatment of
advanced head and neck cancer patients.
1. Introduction
The major goal of cancer treatment is to improve the clinical
outcome by increasing the therapeutic ratio (TR). Most
commonly, the therapeutic ratio is quantitatively defined as
the ratio between tumour control probability (TCP) and
normal tissue complication probability (NTCP). In order
to maximise the therapeutic ratio, tumour control needs to
increase while normal tissue complications need to decrease.
As with any other malignancy, the objective in the treatment
of advanced head and neck cancer is to improve TR through
both components: TCP and NTCP.
After decades of treatment optimisation via novel irradi-
ation techniques, new cytotoxins and several adjuvant agents
to improve tumour response to therapy, advanced unre-
sectable head, and neck cancers are still a clinical challenge.
Although the locoregional control showed improvement
along the implementation of new treatment techniques, the
death rate does not seem to decline for this malignancy [1].
Several randomised clinical trials showed a significant
improvement in locoregional tumour control and disease-
free survival when radiation was combined with cisplatin, as
compared to radiation as a single agent [2, 3], reason why
concurrent cisplatin-based chemoradiotherapy is nowadays
the standard of care for advanced head and neck cancer
patients.
Cisplatin is a platinum compound with complex prop-
erties when it comes to radiation-drug interaction. Through
inhibition of DNA repair and cell cycle arrest cisplatin
demonstrates radiosensitizing properties [4]. Furthermore,
cisplatin exhibits radiosensitization of hypoxic cells due to
scavenging of hydrated electrons by the platinum complex
and formation of local concentrations of OH radicals, which
eventually damage the DNA. Cisplatin was shown to have
cytostatic properties by blocking the cells in the G2 phase of
the mitotic cycle. It was demonstrated that cell cycle arrest
at G2 is relevant to the in vivo action of cisplatin as subse-
quent lethal mitosis may be the most significant mechanism
of cell death induced by this drug [5]. One of cisplatin’s
properties which is yet to be elucidated is the suppression of
tumour neovascularization [6]. Yoshikawa et al. examined the
effect of cisplatin on endothelial cell proliferation observing
significant inhibition of endothelial cell growth for clinical
drug concentrations. To date, the most important property
of cisplatin as confirmed by preclinical and clinical studies
is the ability to form DNA adducts. Cisplatin can form
both intrastrand and interstrand adducts with the DNA [7].
Despite the low number of interstrand crosslinks (less than
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1% of the total adducts) it was considered that these adducts
are responsible for cisplatin’s cytotoxic effect [8]. At the same
time, there are studies relating cisplatin’s cytotoxicity to the
DNA-intrastrand crosslinks [9].
Irrespective of the exact mechanism that leads to radio-
sensitization cisplatin is a powerful drug, and since its clinical
implementation it remains a fundamental cytotoxic agent for
the management of head and neck cancer.
2. Challenges Imposed by Radiotherapy
Tumour hypoxia and accelerated proliferation of tumour
cells during therapy (both radiotherapy and chemotherapy)
remain some of the biggest challenges concerning the treat-
ment of advanced head and neck cancer.The unpredictability
of acute hypoxia in tumours often leads to treatment failure,
and so does the rapid proliferation of tumour cells after
the initiation of therapy. Cellular recruitment from the
quiescent phase, accelerated accelerated stem cell division,
abortive division, and loss of asynchronous stem cell division
are thought to be the main mechanisms responsible for
accelerated regrowth in squamous cell carcinomas of the head
and neck [10–13]. Perhaps the most efficient method to over-
come this burden is the alteration of standard fractionation
in radiotherapy into hyperfractionated and/or accelerated
radiotherapy. Several clinical trials confirmed the superiority
of altered fractionation schedules in regard to tumour control
as compared to standard (conventional) fractionation [14, 15].
Although altered fractionation increased locoregional
control, there were trials that showed no treatment gain
because of normal tissue complications. For instance, in the
EORTC 22851 randomised trial [16], where hyperfraction-
ated-accelerated radiotherapy was compared with the con-
ventionally fractionated regimen, late toxicity nullified the
gain in tumour control. The most common acute toxicities
after radiotherapy reported in head and neck cancer patients
are weight loss due to difficulties in swallowing, mucositis,
xerostomia, and stomatitis, while dysphagia and late xeros-
tomia are listed among late toxicities. There is, therefore,
a price to pay for a better tumour control, though several
times, normal tissue toxicity is a dose-limiting factor in both
radiotherapy and combined chemoradiotherapy. The result
is often treatment interruption, which further compromises
tumour control.
3. Challenges Imposed by the Administration
of Cisplatin
3.1. Normal Tissue Toxicity. While being one of the most
potent chemotherapeutic agents, cisplatin is highly toxic to
various organs. Nephrotoxicity and ototoxicity are some of
the most commonly reported side effects during cisplatin-
based chemotherapy. Other side effects, such as hematologic
and central nervous system-related toxicities, are often dose-
limiting factors or reason for treatment interruption. The
rate of treatment completion is frequently reported to be
below 100% due to adverse events. New radiotherapy delivery
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Figure 1: Risk of leukaemia as a function of the cumulative dose of
platinum agents (based on Travis 1999 data [20]).
effects due to better tumour conformity, as shown by studies
comparing helical tomotherapy to conventional IMRT [17].
However, there is need for further studies to evaluate the
real benefit of these techniques as the latest results show no
significant difference among tomotherapy, IMRT, and 3D-
CRT regarding normal tissue effects [18].
3.2. Risk of Second Primary Cancers. The risk of developing a
second primary cancer after head and neck cancer treatment
was shown to be strongly linked to the original risk factors,
which initiated the first primary cancer, that is, smoking and
alcohol consumption as well as the oncogenic human papil-
lomavirus [19]. Thus the most common site for developing a
second primary cancer in these patients is also the head and
neck region.
However, there is evidence that chemotherapy, particu-
larly cisplatin, can induce carcinogenesis in patients treated
with this agent for their primary malignancy. While proven
to be toxic to normal tissue since the beginning of its clinical
use, cisplatin was not shown to be carcinogenic until later.
A large clinical study undertaken by Travis et al. showed an
increased risk of leukaemia in patients previously treatedwith
cisplatin [20, 21]. Figure 1 shows the increase in leukaemia
risk together with the increase in cumulative dose of cisplatin.
Although the data was based on a study undertaken on
ovarian cancer patients treated with cisplatin, the findings
may be applicable to head and neck cancer patients also [20].
4. Techniques to Maximise the Therapeutic
Ratio in Head and Neck Cancer
The most commonly used methods to optimise the ther-
apeutic ratio are reviewed below. While some of these
techniques are widely accepted among the medical commu-
nity (altered fractionation, cisplatin-based radiochemother-
apy, and image-guided radiotherapy) others either are less
successful in their clinical implementation or await more
conclusive results (bioreductive drugs, normal tissue radio-
protectors, and chronotherapy).
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4.1. Combined Chemoradiotherapy. There is an extensive
number of trials on head and neck cancer comparing
the clinical effect of combined chemoradiotherapy versus
radiotherapy alone. In order to collate and examine the
results, a metaanalysis of the role of chemotherapy in head
and neck cancer (MACH-NC) was published based on
93 randomised trials (conducted between 1965 and 2000)
[22], which confirmed the superior outcome with combined
chemoradiotherapy as compared to radiotherapy as a sole
agent. While with concomitant chemotherapy a notable
benefit was achieved, the results showed no clear justification
for induction chemotherapy [22]. Still, the absolute benefit
for chemotherapy after a 5-year follow-up period was only
4.5% (for concomitant chemotherapy the absolute benefitwas
6.5%).
The advances in knowledge concerning head and neck
radiobiology over the last few decades lead to clinical imple-
mentation of various altered fractionation schedules with
and without chemotherapy. Altered fractionation radiother-
apy combined with cisplatin-based chemotherapy became
a common practice within the management of advanced
head and neck cancer patients [23]. Intensity modulated
techniques (IMRT) are employed for better tumour confor-
mity either via hyperfractionated or accelerated radiother-
apy concurrently with cisplatin-based chemotherapy. Table 1
presents the most recent phases II and III clinical trial results
employing intensity-modulated radiotherapy and cisplatin-
based chemotherapy for advanced head and neck cancers.
Both tumour control andnormal tissue toxicity are presented,
with variable results.
The studies presented in Table 1 have proven, once
again, that combined chemoradiotherapy leads to increased
locoregional tumour control when compared to radiation
as a sole agent [24]. As also proven before, the outcome of
nasopharyngeal cancer treatment tends to be better than that
of other head and neck cancers [25]. Significantly improved
treatment outcome was reported in the SAKK 10/94 trial in
the combined arm (locoregional failure-free survival at 10
years: 40% versus 32%) [24].
The addition of bevacizumab [26] or cetuximab [27, 28]
for an improved tumour control resulted in tolerable acute
and late toxicity. Cetuximab-specific rash was reported by
both trials.
Although locoregional control is significantly improved
with the conversion of conventional therapy into IMRT, long-
term survival remains at low rates, mainly due to tumour
recurrence.
The mixed results achieved with altered fractionation
combined with chemotherapy suggest that there is need for
a careful selection of patients who would benefit from such
therapy. The RTOG 0129 phase III randomised trial showed
that combining cisplatin with altered fractionation (accel-
erated concomitant boost) does not give superior clinical
results to standard fractionation combined with cisplatin
[29].The followup of 721 patients included in the RTOG 0129
trial presented no differences in the 5-year overall survival
(59% versus 56%,𝑃 = 0.18), disease-free survival (45% versus
44%; 𝑃 = 0.42), or locoregional failure (31% versus 28%; 𝑃 =
0.76). Also, there was no significant difference in the overall
grade 3-4 acute mucositis (33% versus 40%) or grade 3-4 late
toxicity (26% versus 21%) [29]. Differences in radiobiological
parameters, such as hypoxia and proliferation status might
give indication on the patient group that would benefit from
a more aggressive treatment.
One of the main challenges with injectable cisplatin is
normal tissue toxicity. Therefore, the idea of oral administra-
tion of cisplatin was worth testing in order to investigate its
level of tolerability. Tao et al. have designed a dose-escalation
trial where oral cisplatin (CP Ethypharm) was administered
in combination with radiotherapy to 18 head and neck cancer
patients [30]. Four cisplatin dose levels were tested from
10mg/m2/day to 25mg/m2/day. Dose limiting toxicities in
the form of gastrointestinal disorders were experienced for
the highest dose hence the dose recommended for phase
II trial was 20mg/m2/day. Daily small doses of cisplatin
have demonstrated good tolerability in the past even in
injectable form [2]; therefore further studies are warranted to
investigate the advantages of daily oral cisplatin in head and
neck cancer patients.
A new platinum compound is on the horizon, namely,
mitaplatin, which is a fusion between cisplatin and the
orphan drug dichloroacetate previously developed to treat
lactic acidosis [31, 32]. It was shown that mitaplatin elicits
cytotoxic effects upon cisplatin-resistant head and neck
tumour cells [31] by a dual killing mode: cisplatin interacts
with the DNA while the action of the dichloroacetate is
focused on the mitochondria by reversing the mitochondrial
changes that confers cancer cells resistance to apoptosis. The
ability of mitaplatin to selectively target cancer cells in vitro
also with less normal tissue toxicity emerges as a strong
foundation for further in vivo experiments.
4.2. Image-Guided Radiotherapy. Image-guidance represents
today an important tool for increasing the therapeutic gain
by better targeting the tumour, especially during fractionated
radiotherapy when tumour shrinkage is expected over time
and by better sparing of the surrounding normal tissue.
Image-guided radiotherapy can be optimally achieved by
employing cone beam CT during the course of radiotherapy
then adapting the treatment plan according to the new
tumour parameters [33].
Another imaging method, which assists in improving
tumour control in head and neck cancer patients, is PET/CT.
The functional properties supplied by PET together with
the anatomical tumour delineation offered by CT provide
a powerful tool in tumour classification and prediction of
treatment outcome as well as selective targeting of hypoxic
regions within the tumour. Beside 18F-FDG, which is still
considered the standard radiotracer for PET imaging, there
are hypoxia-specific radiotracers (F-MISO, F-FAZA) as well
as proliferation-specific radiotracers (F-FLT) successfully
used in clinical settings [34].
A clinical study conducted by Rothschild et al. [38] em-
ploy-ing image-guided IMRT was undertaken on 131 patients
with locally advanced pharyngeal carcinoma.The aim was to
investigate the role of FDG-PET/CT guidance in predicting
treatment outcome. One treatment arm comprised of 45
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Table 1: Cisplatin-based chemoradiotherapy regimens employing IMRT techniques.
Clinical study Patientno. Radiotherapy Chemotherapy Clinical outcome





42 IMRT total dose of 70Gy
Cisplatin (50mg/m2 on
days 1, 2, 22, 23, 43, and 44)
and bevacizumab (15mg/kg
on days 1, 22, and 43)
TCP progression-free survival
rate at 2 years: 75.9%; overall
survival rate at 2 years: 88%
NTCP , no increased toxicity
with the addition of
bevacizumab.
Phase III trial (SAKK 10/94)







Median total dose of
74.4Gy, 1.2 Gy twice daily 5
days per week
Two cycles of cisplatin
(20mg/m2 for 5
consecutive days during
weeks 1 and 5)
TCP locoregional failure-free
survival at 10 years: 40% versus
32%; metastasis-free survival:
56% versus 41%; cancer-specific
survival at 10 years: 55% versus
43% in the combined arm versus
radiotherapy alone
NTCP, no difference in late
toxicity.






30 IMRT median dose of70Gy
Cetuximab: initial dose of







NTCP grade 3-4 oropharyngeal




(20%) and 10% grade 3
cetuximab-related acneiform
rash.









70Gy of 1.25Gy twice daily
fractions. Intermediate and
low-risk PTVs of 60Gy and
50Gy, at 1.07 and
0.89Gy/fraction
Cisplatin 33mg/m2 weekly
TCP actuarial 3-year overall
survival: 80%, progression-free
survival: 82%, and locoregional
control:87%
NTCP grade 3 + toxicities
mucositis (38%), fatigue (28%),
dysphagia (28%), and leukopenia
(26%).






integrated boost (67.5, 60,
and 54Gy in 30 daily
fractions of 2.25, 2, and
1.8Gy)
Cisplatin 40mg/m2 weekly




TCP complete response: 74.4%;
estimated 5-year locoregional
control: 82%;
NTCP tolerable acute and late
toxicities.







IMRT of 69-70Gy at
2.12–2.3 per fraction










NTCPmild to moderate. Grade 3
stomatitis (27%), all other
toxicities (less than 10%).






Median dose of 70Gy at
2.12 Gy/fraction to the
PTVGTV; 59.4Gy at
1.8 Gy/fraction to the PTV
of high-risk subclinical
disease
Cisplatin 2 to 3 cycles
100mg/m2 intravenously




survival: 94%; overall survival
63%
NTCP grade 2 + mucositis
occurred in 48% of patients; all
had Grade 2 + pharyngitis during
treatment.
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patients treated with PET/CT-based IMRT was control-
matched with the second arm that included 86 patients
treated with CT-based 3D conformal radiotherapy without
image guidance. The 2-year overall survival for the PET/CT-
IMRT arm was 91%, while in the control group only 54%
of the patients were still alive 2 years after treatment. The
significant increase in survival among the image-guided
group shows the high potential of PET/CT in personalizing
radiotherapy for head and neck cancer patients.
An innovative radiation therapy trial is currently accruing
patients for analysing the predictive value of biological
markers and 89Zr-cetuximab uptake in head and neck
cancer treated with cisplatin versus cetuximab and standard
radiotherapy versus redistributed radiotherapy. The focus of
the ARTFORCE trial is on individualised treatment, using
functional imaging for the assessment of dose escalation
to the FDG-PET positive region and adaptive replanning
accounting for anatomical changes during treatment [39].
4.3. Epidermal Growth Factor Receptor (EGFR) Inhibitors.
The epidermal growth factor receptor (EGFR) plays a vital
role in head and neck cancer development, growth, and
metastatic spread and angiogenesis, owing to promotion of
epidermal cell growth and regulation of cell proliferation. It
was clinically proven that overexpression of EGFR leads to
increased tumour proliferation and other growth-promoting
behaviour. Of all head and neck squamous cell carcinomas
a value as high as 90% exhibits overexpression of epidermal
growth factor receptor [40].
A clinical trial conducted by Bonner et al. [41] aimed to
investigate the efficacy of cetuximabwhen given concurrently
with radiation as compared to radiotherapy alone. In the
trial, 213 patients were randomised to radiotherapy alone and
211 patients to radiotherapy with cetuximab. The addition
of cetuximab to radiotherapy significantly increased both 3-
year locoregional control rates (47% versus 34%) and overall
survival rates (55% versus 45%).The main cetuximab-related
toxicitieswere acneiform rash andhypomagnesemia [41].The
group has also reported on the 5-year survival data while
attempting to find a relationship between survival and the
cetuximab-related rash [42]. Based on their clinical observa-
tions, patients enrolled in the cetuximab arm who developed
grade 2+ cetuximab-induced rash had an improved overall
survival compared to those patients who only presented with
a mild rash.
The combined effect of cetuximab and cisplatin-based
chemoradiotherapy was studied in a phase II trial for patients
with advanced head and neck cancer [43]. Cetuximab was
administered on a weekly basis concurrently with cisplatin
(on weeks 1 and 4) and radiotherapy (with a boost dose for
the last 2 weeks). Although the 3-year overall survival rate
and locoregional control were 76% and 71%, respectively, the
study was closed due to unexpected and significant adverse
events.
Another anti-EGFR monoclonal antibody investigated
as an agent for targeted therapies in head and neck cancer
is panitumumab. As shown by preclinical studies, panitu-
mumab has higher affinity for EGFR than other monoclonal
Table 2: The circadian rhythm of normal oral mucosa cells (data
from Bjarnason et al. [37]).
Cycle phase Early G1 Late G1 S G2 M
Peak time 6 am 11 am 3 pm 4 pm 9pm
Phase marker p27 p53 cyclin E cyclin A cyclin B
antibodies developed to target EGFR [44].Thismight explain
the results of a phase I dose-escalation trial of panitumumab
and paclitaxel combined with intensity modulated radiother-
apy and carboplatin which indicated a high activity of the
EGFR blocking antibody with well-tolerated side effects and
an overall complete response rate of 95% [45]. Further studies
to elucidate the long-term clinical effect of this agent are
warranted.
4.4. Antiangiogenic Drugs. Angiogenesis inhibitors target
those signalling molecules which stimulate the endothelial
cells to migrate, divide, and form new blood capillaries. One
such signalling molecule is the vascular endothelial growth
factor (VEGF). Antiangiogenic drugs bind to VEGF before
they could connect with the receptors of the endothelial cell
to initiate the angiogenic process.
An angiogenic inhibitor that recognises and binds to
VEGF is bevacizumab, a monoclonal antibody which was the
first agent of its kind to slow tumor growth in glioblastoma,
nonsmall cell lung cancer, and metastatic colorectal cancer
patients [46]. Fury et al. [26] reported the results of a phase II
clinical trial for advanced head and neck cancer that involved
bevacizumab and cisplatin-based chemotherapy combined
with intensity-modulated radiotherapy (see also Table 1).
Progression-free survival rate at 2 years was 75.9% with an
overall survival rate at 2 years of 88%. No increased toxicity
with the addition of bevacizumab was reported.
An interesting study undertaken by Wang et al. [47]
investigated the effect of bevacizumab, cetuximab, and cis-
platin in various combinations on head and neck carci-
noma in mice. Based on the results, the highest tumour
control (expressed by the delay in tumour growth) and
the maximum survival were achieved in a double-agent
combination (bevacizumab-cisplatin) rather than the triple-
agent combination of cetuximab-bevacizumab-cisplatin. The
high apoptotic index in the triple-agent study as compared
to the double-agent one (31.6 ± 12.0% versus 6.9 ± 1.3%)
suggests that there might be an antagonistic effect of the
monoclonal antibodies when administered together and also
in combination with the platinum agent.
The same research group showed that bevacizumab has
antitumour effect beyond antiangiogenesis, potentiating the
cytotoxicity of cisplatin on squamous cell carcinomas [48].
The chemosensitizing property of bevacizumab was evi-
denced by in vivo studies via intratumoral injection. While
the mechanism behind this behaviour is unclear, the results
warrant further investigations.
4.5. Normal Tissue Radioprotectors. The rate and degree of
normal tissue toxicity in head and neck cancer patients
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treated with radiation have justified the clinical need for a
normal tissue radioprotector for reduction of side effects.
Amifostine is a commonly used normal tissue radiopro-
tector, which has been trialled in combination with both
radiotherapy and chemoradiotherapy. Amifostine was also
proven to be an effective cytoprotector against the side
effects caused by cisplatin [49]; therefore it was widely
administered in cisplatin-based chemoradiotherapy for head
and neck cancer [50]. Nevertheless, the results of clinical
trials employing amifostine were inconclusive regarding the
effect of this agent on the clinical outcome. To shed some light
on the controversies raised by the use of amifostine, Bourhis
et al. [51] analysed 12 trials encompassing 1119 patients (65%
head and neck cancer patients) treated with radiotherapy ±
chemotherapy. The conclusion of this metaanalysis was that
amifostine did not have a negative impact on overall survival
or progression-free survival.
The future use of amifostine remains uncertain owing to
conflicting results regarding normal tissue toxicities. While
some of amifostine’s properties such as selectivity (i.e., lack
of tumour protection) and safety were confirmed by several
studies, the reduction in normal tissue toxicity was not always
demonstrated [52].
4.6. Chronotherapy. It is a known and accepted fact that
biological functions in humans are organised around a
circadian (day/night) clock. Circadian rhythms are controlled
by the suprachiasmatic nucleus of the hypothalamus, also
known as the “master pacemaker”. Consequently, several
biological processes are dictated by this clock including sleep,
hormone secretion, and cell proliferation. Experimental find-
ings suggest the existence of crosstalk between clock gene
molecules and those molecules, which are responsible for
cellular progression through the cell cycle [53].
Chronotherapy refers to treatment that is timed around
this biological clock, which was shown to differ between
normal and cancer cells [54, 55]. Chronotherapy could assist
in reducing normal tissue toxicity in cancer patients if drugs
pharmacokinetics and their target organs are known and
understood.
One of the most common side effects during and after
chemoradiotherapy of head and neck cancers are those
involving the oral mucosa. The goal of chronotherapy is to
take into account the biological clock of various tissues in
trying to schedule treatment in the most opportune time for
the tumour and the least harmful time for the normal cells.
Therefore, investigating the peak times of oral mucosa cells
could dictate the timing of treatment to diminish side effects.
Bjarnason et al. have investigated the circadian variation
of human oral epithelium through the expression of cell-
cycle proteins [37] and verified the findings in a randomised
clinical trial of 205 head and neck cancer patients [56]. The
study concerning the circadian rhythm of the oral mucosa
cells involved samples from healthy male volunteers and
showed that cells in the S phase peaked around 3 pm, whereas
cells in the M phase had their peak in the evening (Table 2).
Experimental studies support the evidence whereby the
DNA synthesis rhythm in normal cells is in phase opposition
with that of tumour cells, observation that is valid for
the mitotic phase as well [54, 57]. Consequently, the most
optimum treatment time for a high tumour cell kill would
be in the morning, when most target cells are transitioning
G
2
/M. During this time, normal cells would receive better
protection, as they peak in G
1
.
There are clinical studies supporting the evidence where-
by treatment timing according to cellular circadian rhythm
can improve treatment outcome in head and neck cancer
patients. Bjarnason et al. [56] conducted a randomised trial
to verify the advantage of morning radiotherapy versus
afternoon radiotherapy from a normal tissue perspective.
They hypothesised that morning radiotherapy will lead to
less normal tissue effects involving the oral mucosa, as oral
epithelial cells peak in G
1
. Patients were randomised to
morning (8–10 am) versus afternoon (4–6 pm) radiotherapy.
The results showed a significant improvement in weight loss
for the morning group as compared to patients receiving
radiotherapy in the afternoon and reduced incidence of oral
mucositis among male patients (49.4% versus 64.1%). It was
suggested that a greater treatment time difference between
the two arms could have lead to a greater advantage of
morning radiotherapy.
It was shown that circadian dosing time could also
influence drug-related toxicities [58]. Consequently, cisplatin
should be less toxic to normal tissue if administered around
4 pm when the target organs (such as kidney and bone
marrow) are less susceptible to cisplatin-caused damage.
Positive results confirming the preclinical findings of plat-
inum chronotherapy were reported by Focan et al. [59] in
a study undertaken on oesophageal cancer patients. Normal
tissue toxicity was considered excellent, with grade 3-4 oral
mucositis occurring in only 11–23% patients, leucopenia in 6–
19%, and thrombopenia in 18–50%.
The results achieved with chronotherapeutics in leukae-
mia patients, ovarian cancer patients, andmetastatic colorec-
tal cancer patients are even more pronounced. For instance,
a twofold increase in survival and disease free rate after 5
yearswas reported in a chronotherapy trial involving children
with acute lymphoblastic leukaemia when chemotherapy
(antimetabolites) was administered in the evening (80%
survival) versus morning treatment (40% survival) [60, 61].
The results indicate that malignant lymphoblasts are more
susceptible to antimetabolites in the evening than in the
morning hours.
To obtain conclusive results with head and neck cancer
chronotherapy, there is need for further studies involving
a multidisciplinary approach and an open-minded atti-
tude towards less orthodox treatment methods that showed
promising results in the past.
5. Conclusions
Advanced head and neck cancers are difficult to manage
despite the large treatment arsenal currently available. The
multidisciplinary effort to increase disease-free survival and
diminish normal tissue toxicity is rewarded with better
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locoregional control and sometimes fewer side effects. Nev-
ertheless, locoregional recurrence is still one of the main
reasons for treatment failure.
In order to increase therapeutic ratio, there are methods
to improve tumour control as well as normal tissue sparing.
Some of the techniques to achieve these goals are listed below.
Techniques to increase TCP:
(i) optimum fractionation schedules;
(ii) optimum timing between radiotherapy and cisplatin
administration based on cisplatin’s pharmacokinetics
and pharmacodynamics as well as the interaction
between cisplatin and radiation;
(iii) knowledge of pretreatment radiobiological tumour
parameters such as oxygenation status and cellular
proliferative capacity;
(iv) image-guidance during radiotherapy;
(v) EGFR inhibitors such as cetuximab;
(vi) angiogenic inhibitors;
(vii) chronotherapy involving knowledge of tumour circa-
dian rhythm.
Techniques to decrease NTCP:
(i) optimum timing between radiotherapy and cisplatin
administration;
(ii) more conformal radiotherapy (IMRT);
(iii) image-guidance during treatment;
(iv) normal tissue radioprotectors such as amifostine;
(v) chronotherapy involving knowledge of normal tissue
circadian rhythms, especially of the oral mucosa
and bone marrow to diminish side effects of both
radiotherapy and chemotherapy.
The latest treatment techniques combined with adjuvant
and/or targeted therapies succeeded in increasing locore-
gional control in advanced head and neck cancer patients.
The downside, however, is the increased rate of side effects.
Furthermore, overall survival in this patient group has not
seen any considerable improvement over the last decades.
While there are promising results with targeted therapies
involving monoclonal antibodies as well as with chronother-
apy, the optimal treatment for advanced head andneck cancer
patients is yet to be established.
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